Key Points
- COO Christopher Franklin Devall sold 140,000 shares of Dominari on Dec. 5 at an average price of $3.82 for $534,800, reducing his stake by 42.33% to 190,702 shares (valued ≈ $728,482).
- He also sold 40,000 shares on Dec. 3 at $4.22 for $168,800, bringing his two recent insider sales to 180,000 shares for total proceeds of $703,600.
- Dominari shares opened at $3.89 and trade well below their 50- and 200-day averages (~$5.41/$5.52); the company has a market cap of ~$62.3M, a 52-week range of $0.83–$13.58, ~42.5% institutional ownership, and an analyst consensus of Hold.
Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) COO Christopher Franklin Devall sold 40,000 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $4.22, for a total transaction of $168,800.00. Following the sale, the chief operating officer owned 370,702 shares in the company, valued at $1,564,362.44. This represents a 9.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Christopher Franklin Devall also recently made the following trade(s):
- On Friday, December 5th, Christopher Franklin Devall sold 140,000 shares of Dominari stock. The stock was sold at an average price of $3.82, for a total transaction of $534,800.00.
Dominari Stock Performance
NASDAQ DOMH opened at $3.89 on Friday. The firm's 50 day moving average price is $5.41 and its two-hundred day moving average price is $5.52. Dominari Holdings Inc. has a twelve month low of $0.83 and a twelve month high of $13.58. The stock has a market cap of $62.28 million, a price-to-earnings ratio of 0.70 and a beta of 0.68.
Analyst Ratings Changes
Several research firms recently weighed in on DOMH. Wall Street Zen lowered Dominari from a "buy" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Dominari in a report on Tuesday. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has a consensus rating of "Hold".
Read Our Latest Stock Report on Dominari
Institutional Trading of Dominari
Institutional investors have recently bought and sold shares of the company. Magnus Financial Group LLC acquired a new position in Dominari in the 2nd quarter worth about $136,000. Jane Street Group LLC acquired a new stake in shares of Dominari during the 2nd quarter valued at about $158,000. Millennium Management LLC bought a new stake in shares of Dominari in the 3rd quarter valued at approximately $213,000. Geode Capital Management LLC increased its holdings in Dominari by 2.9% in the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock worth $361,000 after buying an additional 1,866 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in Dominari in the third quarter worth approximately $771,000. Institutional investors and hedge funds own 42.48% of the company's stock.
About Dominari
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
